Did you mean?
Search Results - Showing 12 - 24 Of 50
_at-100-recombinant-human-surfactant-protein-d.jpg "AT-100 is a recombinant form of human surfactant protein-D (rhSP-D). SP-D, absent from current therapies, is a normal protein component of lung surfactant that performs three critical roles in maintaining healthy lung function.nn1. Surfactant Homeostasisn2. Immunomodulatoryn3. Anti-inflammatorynnAT-100 augments current therapy:n- Current therapy is commercial lung surfactant—40% of very low birth weight babies don’t respond to this therapyn- AT-100 adds back the missing surfactant protein-Dn")
⏲ 1 min 17 sec ✓ 26-Sep-2017
_immunomodulatory-therapy-for-fl-the-r-regimen.jpg "OncLiveTV")
⏲ 3 minutes 36 seconds 👁 154
_current-and-future-directions-for-novel-therapy-for-multiple-myeloma-paul-g-richardson-md.jpg "Dana-Farber Cancer Institute")
⏲ 37 minutes 46 seconds 👁 930
_myeloma-treatment-decisions-whats-right-for-you.jpg "When choosing an myeloma treatment, what should be considered? Dr. Peter Forsberg, a myeloma specialist, reviews key decision-making factors, treatment options for myeloma, including combination approaches, and shares advice on advocating for yourself. nnDr. Peter Forsberg is assistant professor of medicine at the University of Colorado School of Medicine and is a specialist in multiple myeloma. More about Dr. Forsberg here: https://www.cudoctors.com/Find_A_Doctor/Profile/24672.")
⏲ 19 min 38 sec ✓ 02-Dec-2020
_what-are-immunomodulatory-drugs-imids-and-how-do-they-work.jpg "HealthTree University Myeloma")
⏲ 2 minutes 53 seconds 👁 1.4K
_update-on-diagnosis-and-therapy-of-plasma-cell-dyscrasias.jpg "UWDeptMedicine")
⏲ 58 minutes 41 seconds 👁 277
_molecular-pathways-associated-with-immune-modulation-and-thalidomide-analogues.jpg "Dr Chopra talks to ecancertv at the 1st Immunotherapy of Cancer Conference ( ITOC ) in Munich about a newly discovered mechanism of action for immunomodulatory thalidomide analogues.nnThese act by modulating the way certain proteins are degraded, thus preventing the growth of certain tumours such as lymphoma.nnThis also negatively affects B-Cell development, but in turn activates T-Cells.nnThe therapy could be combined with other antibodies and vaccines.")
⏲ 2 min 66 sec ✓ 09-Jan-2018
_immunomodulatory-drugs-imids-advances-in-disease-pathogenesis.jpg "ClevelandClinicCME")
⏲ 25 minutes 24 seconds 👁 600
_how-immunomodulatory-drugs-have-reinforced-the-value-of-the-immune-system-in-multiple-myeloma.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 3 minutes 6 seconds 👁 239
_what-are-currently-available-myeloma-treatments.jpg "Dr. Omar Nadeem reviews myeloma treatment classes, including immunomodulatory therapies, proteasome inhibitors, and monoclonal antibodies. Dr. Nadeem also discusses how combining these therapies has boosted the effectiveness of myeloma treatment.n nDr. Omar Nadeem is the Clinical Director of the Myeloma Immune Effector Cell Therapy Program and Associate Director of the Multiple Myeloma Clinical Research Program at the Dana-Farber Cancer Institute. Learn more about Dr. Nadeem, here: https://www.d")
⏲ 1 min 50 sec ✓ 09-Dec-2022
_immunodulatory-therapy-for-allergic-disorders-lanny-rosenwasser-md.jpg "ACAAICOLA")
⏲ 54 minutes 37 seconds 👁 156
_relapsed-refractory-multiple-myeloma-124-current-treatment-options-124-options-on-the-horizon.jpg "Multiple Myeloma Research Foundation - MMRF")
⏲ 51 minutes 36 seconds 👁 2.2K
Related Searches
Search Videos
Recent Searches
_at-100-recombinant-human-surfactant-protein-d.webp "AT-100 is a recombinant form of human surfactant protein-D (rhSP-D). SP-D, absent from current therapies, is a normal protein component of lung surfactant that performs three critical roles in maintaining healthy lung function.nn1. Surfactant Homeostasisn2. Immunomodulatoryn3. Anti-inflammatorynnAT-100 augments current therapy:n- Current therapy is commercial lung surfactant—40% of very low birth weight babies don’t respond to this therapyn- AT-100 adds back the missing surfactant protein-Dn")
_immunomodulatory-therapy-for-fl-the-r-regimen.webp "OncLiveTV")
_current-and-future-directions-for-novel-therapy-for-multiple-myeloma-paul-g-richardson-md.webp "Dana-Farber Cancer Institute")
_myeloma-treatment-decisions-whats-right-for-you.webp "When choosing an myeloma treatment, what should be considered? Dr. Peter Forsberg, a myeloma specialist, reviews key decision-making factors, treatment options for myeloma, including combination approaches, and shares advice on advocating for yourself. nnDr. Peter Forsberg is assistant professor of medicine at the University of Colorado School of Medicine and is a specialist in multiple myeloma. More about Dr. Forsberg here: https://www.cudoctors.com/Find_A_Doctor/Profile/24672.")
_what-are-immunomodulatory-drugs-imids-and-how-do-they-work.webp "HealthTree University Myeloma")
_update-on-diagnosis-and-therapy-of-plasma-cell-dyscrasias.webp "UWDeptMedicine")
_molecular-pathways-associated-with-immune-modulation-and-thalidomide-analogues.webp "Dr Chopra talks to ecancertv at the 1st Immunotherapy of Cancer Conference ( ITOC ) in Munich about a newly discovered mechanism of action for immunomodulatory thalidomide analogues.nnThese act by modulating the way certain proteins are degraded, thus preventing the growth of certain tumours such as lymphoma.nnThis also negatively affects B-Cell development, but in turn activates T-Cells.nnThe therapy could be combined with other antibodies and vaccines.")
_immunomodulatory-drugs-imids-advances-in-disease-pathogenesis.webp "ClevelandClinicCME")
_how-immunomodulatory-drugs-have-reinforced-the-value-of-the-immune-system-in-multiple-myeloma.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_what-are-currently-available-myeloma-treatments.webp "Dr. Omar Nadeem reviews myeloma treatment classes, including immunomodulatory therapies, proteasome inhibitors, and monoclonal antibodies. Dr. Nadeem also discusses how combining these therapies has boosted the effectiveness of myeloma treatment.n nDr. Omar Nadeem is the Clinical Director of the Myeloma Immune Effector Cell Therapy Program and Associate Director of the Multiple Myeloma Clinical Research Program at the Dana-Farber Cancer Institute. Learn more about Dr. Nadeem, here: https://www.d")
_immunodulatory-therapy-for-allergic-disorders-lanny-rosenwasser-md.webp "ACAAICOLA")
_relapsed-refractory-multiple-myeloma-124-current-treatment-options-124-options-on-the-horizon.webp "Multiple Myeloma Research Foundation - MMRF")
![[+]](/images/menu.gif){kind=small}